bioboostresearch.com

The Endocrine System

Labs Explore BioBoost Labs
Body & Peptide Science · System 04

The Endocrine System

A research-use-only look at how GHRH analogs, growth-hormone secretagogues, and gonadal-signaling peptides are studied at the level of mechanism.

9 compounds studied14 primary sourcesResearch use only
Anatomical bio-scan of the The Endocrine System
01

The system at a glance

The endocrine system is a network of glands that release hormones into the blood to coordinate growth, metabolism, and reproduction. Two circuits anchor this page: the growth-hormone (GH) axis, where the hypothalamus releases GHRH to prompt the pituitary to secrete GH, and the reproductive axis, where hypothalamic GnRH drives the pituitary to release LH and FSH. The compounds below are studied because each one nudges a specific receptor within these circuits. None of this is medical guidance; it is a summary of what the research literature documents.

02

How it signals

Peptide hormones work by binding cell-surface receptors, mostly G-protein-coupled receptors, that trigger internal signaling cascades rather than entering the cell. Timing and pattern matter as much as presence: the GH and reproductive axes are naturally pulsatile, and researchers have repeatedly found that steady, continuous exposure to a signal can desensitize a receptor and blunt the very response a brief pulse would stimulate. The studied compounds differ mainly in which receptor they hit, how selective they are, and how long they persist in circulation.

The HPA axis stress-response cascade: hypothalamus CRH to pituitary ACTH to adrenal cortisol with negative feedback
The HPA axis — the hypothalamic–pituitary–adrenal stress cascade (CRH → ACTH → cortisol) with negative feedback.
03

Research peptides studied in this system

Each card summarizes the documented mechanism, what was actually studied and in what model, and how strong the evidence is. These are descriptions of laboratory research — not recommendations, and not evidence of benefit in humans. According to research indexed in PubMed:

CJC-1295 (DAC)long-acting hGRF(1-29) analog with Drug Affinity ComplexModerate — early human pharmacology data
Documented mechanism
A modified fragment of growth-hormone-releasing hormone that acts as an agonist at the pituitary GHRH receptor to stimulate GH release. Its Drug Affinity Complex (a maleimide group) covalently binds a cysteine on circulating serum albumin, which shields it from rapid breakdown and greatly extends how long it persists in the blood. 123
What was actually studied
In a randomized, placebo-controlled trial in healthy adults, single subcutaneous doses produced dose-dependent, multi-day increases in GH and IGF-I, with an estimated half-life of roughly 6-8 days. The albumin-binding mechanism was first characterized in rats.
Evidence tier
Investigational compound, not an approved medicine. Published human data are limited to small early-phase pharmacology and safety studies; long-term outcomes are not established.
CJC-1295 (no-DAC)modified GRF(1-29) without Drug Affinity ComplexLow — mechanism inferred, minimal dedicated human data
Documented mechanism
The same GRF(1-29)-based GHRH-receptor agonist backbone but lacking the albumin-binding Drug Affinity Complex. Without covalent attachment to serum albumin it is not protected from rapid enzymatic degradation, so it is expected to act far more briefly than the DAC version. 23
What was actually studied
The no-DAC form appears mainly in analytical and anti-doping method-development literature that characterizes GHRH-analog metabolites; it has not been the subject of the published human pharmacology trial that examined the DAC version.
Evidence tier
Investigational; the human half-life and pharmacodynamic data commonly cited for ‘CJC-1295’ come from the DAC form and should not be assumed to apply here.
SermorelinGRF(1-29), GHRH(1-29)NH2Moderate — historical clinical study in humans
Documented mechanism
A synthetic peptide corresponding to the first 29 amino acids of endogenous GHRH, which retains the biologically active region. It binds the pituitary GHRH receptor to stimulate pulsatile GH secretion, then is cleared quickly like native GHRH. 34
What was actually studied
GHRH(1-29) analogs have been evaluated in humans as probes of pituitary function and, historically, in children with GH deficiency; review literature documents acute GH rises after administration.
Evidence tier
Sermorelin has a history of clinical/diagnostic use as a GHRH agent, so it is better characterized than most peptides here; even so, this page describes mechanism only and not any therapeutic protocol.
GHRH Analoggrowth-hormone-releasing hormone analog (compound class)Moderate — class includes an approved agent
Documented mechanism
An umbrella term for peptides engineered to mimic endogenous GHRH at the pituitary GHRH receptor, stimulating GH (and downstream IGF-I) release. Analogs are typically modified to resist the enzymes that rapidly inactivate natural GHRH. 34
What was actually studied
The class has been studied in animals and humans; tesamorelin is an FDA-approved GHRH analog, and analytical work has characterized the metabolism of several synthetic members including sermorelin, tesamorelin, and CJC-1295.
Evidence tier
The term covers a range of molecules with very different levels of evidence; at least one member is an approved medicine while others remain investigational. Claims true of one analog do not automatically transfer to another.
Ipamorelingrowth-hormone secretagogue, ghrelin-receptor agonistLow — largely preclinical
Documented mechanism
Works through a different receptor than the GHRH analogs: it is a selective agonist of the ghrelin receptor (GHS-R1a), a growth-hormone secretagogue pathway that stimulates GH release and is reported to be relatively selective for stimulating GH release. 56
What was actually studied
Characterized in cell and rodent studies of ghrelin-receptor binding and GH release, and investigated in a rodent model of post-operative ileus for effects on gut motility. Human efficacy data are limited.
Evidence tier
Investigational compound, not an approved medicine; most published mechanism and effect data come from animal and in-vitro work rather than controlled human trials.
Kisspeptin-10KP-10, metastin(45-54)Moderate — human mechanistic studies
Documented mechanism
Acts upstream of the reproductive axis as an agonist at the kisspeptin receptor (KISS1R / GPR54) on GnRH neurons, prompting them to release GnRH, which in turn drives pituitary LH and FSH secretion. 78
What was actually studied
In healthy human volunteers, kisspeptin isoforms stimulate LH release as a readout of GnRH activity; brief exposure produces sustained GnRH release, while continuous exposure causes desensitization. A related isoform, kisspeptin-54, has been studied as a diagnostic probe of hypothalamic GnRH-neuron function in congenital hypogonadotropic hypogonadism.
Evidence tier
Studied as a physiologic and diagnostic tool rather than an approved therapy. This entry is strictly mechanistic; it makes no claim about fertility, libido, or any lifestyle outcome.
hCGhuman chorionic gonadotropinHigh — approved medicine with robust clinical data
Documented mechanism
Structurally similar to LH and acts as an agonist at the shared LH/choriogonadotropin receptor (LHCGR) on gonadal cells (Leydig cells in males, theca/granulosa in females), driving steroidogenesis such as testosterone production. Genetic studies of inactivating LHCGR mutations map how essential this receptor is to reproductive development. 910
What was actually studied
Extensively studied in humans. In men with hypogonadotropic hypogonadism, hCG (often combined with FSH) has been shown in clinical trials to restore spermatogenesis in a majority of treated patients.
Evidence tier
hCG is itself an approved medicine (used clinically in ovulation induction and in male hypogonadism/fertility); it is a well-characterized drug, not an experimental research peptide, and its clinical use is directed by physicians.
OxytocinOTHigh — approved medicine, large literature
Documented mechanism
A nine-amino-acid neuropeptide that binds the oxytocin receptor, a G-protein-coupled receptor, and can also interact with the closely related vasopressin receptors. Classic endocrine actions include uterine smooth-muscle contraction and milk ejection; it also acts centrally in social and stress-related physiology. 11
What was actually studied
One of the most extensively studied neuropeptides in both animals and humans. Review literature emphasizes that its chemistry, overlap with vasopressin signaling, context-dependence, and measurement difficulty make its non-reproductive effects hard to pin down.
Evidence tier
Oxytocin is an approved medicine for defined obstetric uses (for example labor induction and control of postpartum bleeding). Many of its widely discussed behavioral and ‘wellness’ effects remain investigational and inconsistent across studies.
Melanotan IIMT-II, cyclic alpha-MSH analogLow — unlicensed; preclinical mechanism plus safety case reports
Documented mechanism
A synthetic cyclic analog of alpha-melanocyte-stimulating hormone that acts as a non-selective agonist across melanocortin receptors, including MC1R (skin pigmentation) and central MC3R/MC4R (appetite and energy-balance signaling). 121314
What was actually studied
Melanocortin-receptor agonism has been characterized in rodent studies of appetite suppression and of peripheral-nerve regeneration. In humans, MT-II has appeared largely as unlicensed self-injection, and dermatology case reports document cutaneous melanoma and intense pigmentation changes in users.
Evidence tier
Unlicensed and incompletely tested; its full adverse-effect profile is unknown. Reported risks include changes to pigmented skin lesions and melanoma. This entry is deliberately limited to receptor mechanism and documented safety signals.
04

What we don’t know — and the risks

Honest limits matter as much as the mechanisms. For this system specifically:

  • Research-use-only: none of these compounds are described here for personal use, and this page gives no dosing, timing, route, or administration guidance of any kind.
  • Evidence tiers vary widely — hCG and oxytocin are approved medicines with large human datasets, while ipamorelin, the no-DAC CJC-1295 form, and Melanotan II rest mainly on animal or in-vitro data or on uncontrolled human use.
  • The GH and reproductive axes are pulsatile and tightly interlinked; pushing one receptor can trigger feedback, desensitization, or downstream hormonal shifts that a single-target description does not capture.
  • Unlicensed injectable peptides carry documented safety signals — Melanotan II has been linked in case reports to melanoma and pigmented-lesion change, and purity, dosing accuracy, and contamination are unverifiable outside regulated manufacturing.
  • Human efficacy claims should be trusted only where a real human trial supports them; for several compounds the striking data come from short early-phase or animal studies, not long-term outcomes.
  • Endocrine questions involving fertility, growth, or hormone balance are clinical matters for a licensed physician, not something to self-manage from mechanism summaries.
05

Responsible understanding

◆ This is education, not medical advice

This page is educational and describes what has been studied in laboratory and clinical research. It is not medical advice, and these materials are for research use only — not for human or veterinary use. Timing, administration, and whether anything is used at all are clinical decisions that belong with a licensed physician overseeing your care; we take no position on them. Science and regulation evolve; verify anything important against the primary sources below.

06

Sources

Based on articles retrieved from PubMed. Follow each link to the original paper.

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology and Metabolism. 2006;J Clin Endocrinol Metab. 2006;91(3):799-805. DOI
  2. Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;Endocrinology. 2005;146(7):3052-8. DOI
  3. Memdouh S, Gavrilovic I, Ng K, Cowan D, Abbate V Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis. 2021;Drug Test Anal. 2021;13(11-12):1871-1887. DOI
  4. Grossman A, Savage MO, Besser GM Growth hormone releasing hormone. Clinics in Endocrinology and Metabolism. 1986;Clin Endocrinol Metab. 1986;15(3):607-27. DOI
  5. Fowkes MM, Lalonde T, Yu L, Dhanvantari S, Kovacs MS, Luyt LG Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor. European Journal of Medicinal Chemistry. 2018;Eur J Med Chem. 2018;157:1500-1511. DOI
  6. Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. The Journal of Pharmacology and Experimental Therapeutics. 2009;J Pharmacol Exp Ther. 2009;329(3):1110-6. DOI
  7. Chan YM Effects of kisspeptin on hormone secretion in humans. Advances in Experimental Medicine and Biology. 2013;Adv Exp Med Biol. 2013;784:89-112. DOI
  8. Abbara A, Eng PC, Phylactou M, Clarke SA, Mills E, Chia G, Yang L, Izzi-Engbeaya C, Smith N, Jayasena CN, Comninos AN, et al. Kisspeptin-54 Accurately Identifies Hypothalamic Gonadotropin-Releasing Hormone Neuronal Dysfunction in Men with Congenital Hypogonadotropic Hypogonadism. Neuroendocrinology. 2021;Neuroendocrinology. 2021;111(12):1176-1186. DOI
  9. Latronico AC, Arnhold IJP Inactivating mutations of the human luteinizing hormone receptor in both sexes. Seminars in Reproductive Medicine. 2012;Semin Reprod Med. 2012;30(5):382-6. DOI
  10. Warne DW, Decosterd G, Okada H, Yano Y, Koide N, Howles CM A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin. Fertility and Sterility. 2009;Fertil Steril. 2009;92(2):594-604. DOI
  11. Carter CS, Kenkel WM, MacLean EL, Wilson SR, Perkeybile AM, Yee JR, Ferris CF, Nazarloo HP, Porges SW, Davis JM, Connelly JJ, Kingsbury MA Is Oxytocin “Nature’s Medicine”? Pharmacological Reviews. 2020;Pharmacol Rev. 2020;72(4):829-861. DOI
  12. Eliason NL, Martin L, Low MJ, Sharpe AL Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food. Neuropeptides. 2022;Neuropeptides. 2022;96:102289. DOI
  13. Ter Laak MP, Brakkee JH, Adan RAH, Hamers FPT, Gispen WH The potent melanocortin receptor agonist melanotan-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat. European Journal of Pharmacology. 2003;Eur J Pharmacol. 2003;462(1-3):179-83. DOI
  14. Hjuler KF, Lorentzen HF Melanoma associated with the use of melanotan-II. Dermatology (Basel, Switzerland). 2014;Dermatology. 2014;228(1):34-6. DOI
Body & Peptide Science · The Endocrine System · Draft for review
Research-use-only educational content. Nothing here is medical, dosing, timing, or treatment advice.
For research use only — not for human consumption, and not for diagnosing, treating, curing, or preventing any disease or condition, or making any medical claim. BioBoost Research is an educational resource. Science and regulation are evolving, and the information here may be incomplete, become outdated, or contain errors. Nothing here is medical, legal, or dosing advice — always verify against primary sources and consult a qualified professional. All information reflects facts as best known to BioBoost Research. Full disclaimer →

On clinical data and dosing: Any clinical trials, data, or dosing figures referenced anywhere on this site were conducted in controlled settings under qualified professional and physician oversight, and are shown for informational and educational purposes only — never as guidance. BioBoost Research makes no claim that the same outcome or safety profile would apply to any compound, person, or context. Research and educational use only · 21+.

Read the full Disclaimer →